secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001808805-23-000005
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology reports FY2022 net loss of $57.9M; cash runway into 2025
-------------------------------------------------------------------------------

- Net loss $57.9M for FY2022 vs $50.3M in FY2021; operating expenses $63.6M, up 26%.
- Cash, cash equivalents, and investments $313.6M as of Dec 31, 2022; runway into 2025.
- Strategic partnership with TGen to study Nautilus platform for DIPG childhood cancer.
- Opened San Diego office in University Town Center to expand geographic footprint.
- Q4 2022 expenses below peak Q4 2021 levels, helping preserve cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880523000005/0001808805-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880523000005/naut-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001808805-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer